Cambrian BioPharma is a clinical-stage biopharmaceutical company dedicated to developing therapeutics that treat and prevent diseases of aging. Their mission is to extend healthspan – the period of life spent in good health – by advancing a diverse portfolio of novel drug candidates. Cambrian operates on a 'Distributed Drug Development' (DEAL - Discovery, Evaluation, Acceleration, and Launch) model, identifying and nurturing promising scientific breakthroughs from various sources to build its pipeline companies.
The New York headquarters serves as the central hub for Cambrian BioPharma's global operations, overseeing strategic direction, R&D pipeline management, corporate development, investor relations, and the coordination of its distributed drug discovery model.
Located in a modern office building in the Hudson Square neighborhood, the headquarters provides a contemporary workspace designed to foster collaboration and innovation. Its location offers access to a rich ecosystem of scientific talent, financial institutions, and research organizations.
Cambrian BioPharma fosters a highly ambitious, science-first work culture. Employees are driven by the mission to extend healthspan, working in a dynamic, fast-paced environment that encourages innovation, rigorous research, and cross-functional collaboration. Given its distributed model, effective communication and project management are key cultural aspects.
The headquarters is the nerve center for Cambrian's unique approach to drug development, managing a portfolio of pipeline companies and collaborations aimed at tackling the multifaceted aspects of aging. Its New York presence is vital for attracting top talent and securing investment.
Cambrian BioPharma primarily operates through its New York headquarters and a distributed R&D model. This involves identifying, funding, and developing scientific assets from research institutions and biotech partners globally. While its corporate hub is in the US, its scientific sourcing, collaborations, and the ultimate impact of its therapies are aimed at a global scale to address age-related diseases worldwide.
180 Varick Street, Suite 1228
New York
NY
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cambrian Asset Management' leadership includes:
Cambrian Asset Management has been backed by several prominent investors over the years, including:
The most notable executive update in the past year was the appointment of Brent Saunders as Executive Chairman in January 2024, a significant addition bringing extensive biopharma leadership experience to Cambrian BioPharma. No major executive departures were publicly announced during this period.
Discover the tools Cambrian Asset Management uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Based on publicly available information and common industry practices, Cambrian BioPharma likely utilizes a straightforward email format. The most probable format is using the first name of the employee.
[first]@cambrianbio.com
Format
james@cambrianbio.com
Example
85%
Success rate
PR Newswire • January 9, 2024
Cambrian BioPharma announced that Brent Saunders has joined the company as Executive Chairman. Saunders, a renowned leader in the biopharmaceutical industry, will bring his extensive experience to guide Cambrian's strategy and growth in developing medicines to target diseases of aging....more
PR Newswire • November 9, 2023
Cambrian BioPharma launched Telomere Therapeutics, Inc., a new pipeline company. Telomere Therapeutics will focus on developing novel gene therapies targeting telomere biology, based on technology exclusively licensed from the University of Pittsburgh, to treat and prevent age-related diseases....more
BioSpace • February 7, 2023
Cambrian BioPharma announced a publication detailing the development of novel, highly selective mTORC1 inhibitors. These compounds show potential for improved safety profiles in treating age-related diseases by minimizing off-target effects associated with earlier mTOR inhibitors....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cambrian Asset Management, are just a search away.